Investors focused on the Medical space have likely heard of BioTelemetry (BEAT Quick QuoteBEAT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of BEAT and the rest of the Medical group's stocks.

BioTelemetry is a member of our Medical group, which includes 758 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).

Within the past quarter, the Zacks Consensus Estimate for BEAT's full-year earnings has moved 16.16% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

According to our latest data, BEAT has moved about 85.28% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 5.14% on average. This means that BioTelemetry is outperforming the sector as a whole this year.

Breaking things down more, BEAT is a member of the Medical Services industry, which includes 31 individual companies and currently sits at #88 in the Zacks Industry Rank. On average, stocks in this group have gained 23.21% this year, meaning that BEAT is performing better in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track BEAT. The stock will be looking to continue its solid performance.